---

Global contract development and manufacturing organization (CDMO), Lonza, has announced the completion of its maiden GMP product batch at its new mammalian manufacturing facility in Portsmouth (US).

Lonza Portsmouth focuses on custom production of mammalian biopharmaceuticals and cell therapies.

Since the market for these therapies is rapidly growing, pharmaceutical and biotech businesses must overcome a series of challenges in order to succeed and stay competitive.

Lonza aims to step in and make the acquisition of these products more efficient.

An important milestone has been reached by the company with this first GMP batch release, which enables the facility to support the deployment of high-titer and high-throughput platform procedures and help satisfy the growing market demand for small- to mid-scale volumes of biologics generated from mammals.

“This milestone is a testament to our commitment to delivering industry-leading manufacturing services to our customers, highlighting our continued efforts to support our customers’ needs across their product lifecycle and meet growing market demand for the launch scale,” stated Stefan Egli, Head of the Mammalian Business Unit, Lonza.

---

READ ALSO: Drug shows reduced risk of progression to type 2 diabetes in pre-diabetics

---

In terms of flexibility, small-scale bioreactors offer numerous benefits, including lower initial capital expenditures and operating expenses, which lessen the difficulties associated with volume forecasts during product launches.

The new facility offers clients a dependable path to market for a range of molecule types by utilizing Lonza's biologics license application (BLA) services, improved drug yield, optimized manufacturing procedures, and process analytical technology developments.

It also plays a vital part in Lonza’s capacity to support its customers throughout their entire product lifetime and enhances the current commercial mammalian-derived product manufacturing at 6,000L and 20,000L scales supplied from the Portsmouth location.

“The new 2,000L asset will support small- to mid-volume products, such as innovative therapies targeting rare diseases, and provide the flexibility required for efficient product launches and sustainable lifecycle management across our manufacturing network,” added Stefan.

---

Did you find this insightful? Subscribe for more.

---